Gilead Sciences (BRSE:935700) - Stock Price, News & Analysis

Resumen acción 935700

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Acerca de la empresa

935700 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	5/6
Financial Health	4/6
Dividends	3/6

Recompensas

Cotiza un 62.2% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 7.8%

Los beneficios aumentaron un 32.6% el año pasado

Análisis de riesgos

Acciones altamente ilíquidas

Historial de dividendos inestable

Tiene un alto nivel de endeudamiento

Competidores de Gilead Sciences, Inc.

Basilea Pharmaceutica

SWX:BSLN

CHF486.7m

Roche Holding

SWX:ROG

CHF182.1b

Novartis

SWX:NOVN

CHF187.5b

Lonza Group

SWX:LONN

CHF39.0b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$68.48
52 Week High	US$82.53
52 Week Low	US$66.91
Beta	0.39
1 Month Change	0%
3 Month Change	n/a
1 Year Change	10.45%
3 Year Change	-8.69%
5 Year Change	-11.64%
Change since IPO	-36.06%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	935700	CH Biotechs	Mercado CH
7D	0%	19.6%	-1.5%
1Y	10.5%	19.3%	-1.4%

Rentabilidad frente al sector: 000935700 superó al sector Swiss Biotechs , que obtuvo un rendimiento del -24.8% el año pasado.

Rentabilidad vs. Mercado: 000935700 superó al mercado Swiss, que obtuvo un rendimiento del -0.9% el año pasado.

Volatilidad de los precios

Is 935700's price volatile compared to industry and market?
935700 volatility
935700 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.6%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.6%
10% least volatile stocks in CH Market	1.9%

Precio estable de las acciones: 000935700 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 000935700 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1987	17,000	Dan O'Day	www.gilead.com

Resumen de fundamentos de Gilead Sciences, Inc.

¿Cómo se comparan los beneficios e ingresos de Gilead Sciences con su capitalización de mercado?
Estadísticas fundamentales de 935700
Capitalización bursátil	CHF86.31b
Beneficios(TTM)	CHF5.03b
Ingresos (TTM)	CHF25.11b

17.2x

Ratio precio-beneficio (PE)

3.4x

Ratio precio-ventas (PS)

¿Está 935700 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 935700
Ingresos	US$27.38b
Coste de los ingresos	US$5.63b
Beneficio bruto	US$21.75b
Otros gastos	US$16.26b
Beneficios	US$5.48b

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	4.40
Margen bruto	79.42%
Margen de beneficio neto	20.03%
Ratio deuda/patrimonio	119.7%

¿Cómo se ha desempeñado 935700 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

4.0%

Rentabilidad actual por dividendo

68%

Ratio de pagos

Resumen acción 935700

Recompensas

Análisis de riesgos

Competidores de Gilead Sciences, Inc.

SWX:BSLN

CHF486.7m

SWX:ROG

CHF182.1b

SWX:NOVN

CHF187.5b

SWX:LONN

CHF39.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Recent updates

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Bloom Science, Inc. Appoints Grace E. Colon as Chair of Its Board of Directors

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care At Asco 2023

Gilead Sciences, Inc. Appoints Cindy Perettie Executive Vice President of Kite

Gilead Sciences, Inc. (NasdaqGS:GILD) acquired Xinthera, Inc.

Gilead Sciences, Inc. Announces Updated Positive Results from Three Cohorts of the Phase 2 Trophy-U-01 Study of Trodelvy®

Full year 2022 earnings released: EPS: US$3.66 (vs US$4.96 in FY 2021)

Gilead Sciences, Inc. Announces U.S. FDA Approves Trodelvy in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Gilead Sciences, Inc.

17.2x

3.4x

Beneficios e Ingresos

Dividendos

4.0%

68%